Week In Review: China Bridge Capital Announces $1.5 Billion Precision Medicine Fund

China Bridge Capital, a Beijing investment firm, invested $45 million in iCarbonX, the big-data/AI healthcare start-up, and plans to raise $1.5 billion for a precision healthcare investment fund; Concord Medical, a China radiotherapy-diagnostic company now developing China cancer hospitals, received a $228 million privatization offer from management; Huapont Life Sciences of Chongqing invested $3 million into San Diego's Angionetics for China rights to Angionetics' heart disease treatment; Hong Kong's Uni-Bio Science licensed China rights for its ophthalmic wound healing product to CR Zizhu Pharma; Jiangsu Hengrui Medicine was granted CFDA approval to start clinical trials for its autoimmune disease treatment; Jilin Jian Yisheng's vaccine adjuvant was effective in an animal test of an Ebola vaccine; Changzhou Fangyuan Pharma completed pre-clinical development work on a difficult-to-produce antibiotic for antibiotic-resistant infections; and South Korea's Hanmi Pharma launched Hanmi Ventures to form partnerships that further its open innovation R&D model in China and Korea.